Page 2 - Sera Prognostics News Today

/PRNewswire/ -- The surge in colposcopy device demand is mainly driven by a growing incidence of cervical disorders like cervical cancer and inflammatory...

Los Angeles-based EarlyDiagnostics announced this morning that it has appointed a new, Co-CEO to the company. According to the developer of cancer detection technology, it has appointed Gregory Critchfield as Co-CEO, effective January 1st. The

Sera Prognostics, Inc. (NASDAQ:SERA – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 253,500 shares, an increase of 27.5% from the April 30th total of 198,900 shares. Based on an average daily trading volume, of 180,400 […]

Key Insights Significant control over Sera Prognostics by retail investors implies that the general public has more...

-- Sera Prognostics shares almost tripled after the company said Wednesday it is stopping enrollment in a study evaluating the safety of a preterm birth prevention strategy due to the trials early...

Sera Prognostics Inc. announced that the Data Safety Monitoring Board overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs study...

-- Sera Prognostics shares more than doubled in value in Wednesday morning trade after the company said it is stopping enrollment in a study evaluating the safety of a preterm birth prevention...

By Denny Jacob Sera Prognostics shares more than doubled following news of study efficacy being met. The stock surged to $5.24 in early trading, vs....

Amid another soft session on Wall Street, Sera Prognostics (NASDAQ:SERA) — a specialist in the field of maternal and neonatal health — shook up the market…

/PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative...